MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

Mind Medicine Inc., a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the publication of the first data on the interaction of the selective serotonin uptake inhibitor escitalopram with the acute response to psilocybin in humans. 

Category Press Release

Companies Featured

MindMed
MindMed is one of the largest companies in the psychedelics space and is developing various psychedelics for mental health disorders.